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One such ligand,
[1-(/3-mercapto-/3,/3-cyclopentamethylenepropionic acid, [2] (ALBtnAVP) .
ALVP was prepared using solid phase synthesis with subsequent disulphide bond formation by air oxidation and purification by reverse phase h.p.1.c. ALBtnVP was produced by reacting ALVP with biotinamidocaproate NHS ester (Sigma) followed by purification using h.p.1.c. Rat liver membranes containing the Vla receptor were made as previous described [3] . Bovine kidney medullary membranes containing V2 receptors were prepared essentially as in [4] except that buffers contained bacitracin (lmg/ml) and the final preparation was frozen and stored in the Hepes based buffer used for the production of liver membranes [3] .
Competition binding assays used 
ALVP inhibition of AVP-stimulated glycogen
In competition experiments the kd of ALVP for the Vla receptor and the V2 receptor was 0.36nM and 194nM respectively. Moreover, ALBtnVP retained high affinity for the Via receptor, kd -5.6nM, whilst having a very low affinity for the V2 receptor, kd2540nM. Thus, both ligands are highly selective for the Vla receptor subtype. ALVP antagonized AVPstimulated glycogen phosporylase a with a corrected IC50 of 2.6nM ( Fig.1) . Both ALBtnVP and d(CH2)~jTyr(Me)~AvP inhibited the AVP-induced inositol-lipid breakdown in WRK 1 cells (Fig.2) showing that ALBtnVP is a full antagonist of AVP at the Vla receptor.
InsP
InsPe InsPg Abbreviations: InsP, InsP2 and InsPg, inositol mono-, bisand trisphosphate; cycloAVP, ~( C H~)~T~K ( M~)~A V P [2] .
We have utilized the bifunctional nature of ALBtnVP to localize Via receptors on WRK 1 cells and hippocampal neurons. Our results have shown that receptor bound ALBtnVP can bind both avidin and streptavidin and can be used to visualize cell surface Vla receptors using either electron microscopy (Au-streptavidin) or light microscopy (FITC-avidin).
In summary, our experiments show that ALVP is a convenient AVP analogue to use as a precursor for the development of functional Vla-selective ligands. One such ligand, ALBtnVP, can be used to visualize the Vla receptor and could be utilized in a purification scheme for the receptor protein.
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